These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2935604)

  • 1. Assessment of the patient's response.
    Hansson L
    J Hypertens Suppl; 1985 Nov; 3(2):S65-9. PubMed ID: 2935604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pitfalls in hypertension management--misjudgements in diagnosis and therapy].
    Scholze J; Rautenberg B; Hansen A
    Dtsch Med Wochenschr; 2002 Nov; 127(45):2383-6. PubMed ID: 12422296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond blood pressure control. Effect of antihypertensive therapy on cardiovascular risk factors.
    Maxwell MH
    Am J Hypertens; 1988 Oct; 1(4 Pt 2):366S-371S. PubMed ID: 3056446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
    Larochelle P; Haynes B; Maron N; Dugas S
    Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):771-5. PubMed ID: 15350178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New onset diabetes during antihypertensive therapy.
    Alderman MH
    Am J Hypertens; 2008 May; 21(5):493-9. PubMed ID: 18437139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of some parameters on the blood pressure reduction under treatment: experience from the Hypertension Optimal Treatment Study].
    Mallion JM; Baguet JP; Siché JP; Benkritly A
    Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1049-53. PubMed ID: 9749163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.
    Hemmelgarn BR; Zarnke KB; Campbell NR; Feldman RD; McKay DW; McAlister FA; Khan N; Schiffrin EL; Myers MG; Bolli P; Honos G; Lebel M; Levine M; Padwal R;
    Can J Cardiol; 2004 Jan; 20(1):31-40. PubMed ID: 14968141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.